Mapi Pharma has reported the first clinical results from its once-monthly Cariprazine Depot program, with the initial Phase I/IIa cohort showing no serious adverse events and only mild treatment-related adverse events after a single subcutaneous injection. The findings provide early support for continued development of a long-acting version of cariprazine, an established atypical antipsychotic currently available as a once-daily oral medicine for schizophrenia, bipolar I disorder and major depressive disorder. Mapi Pharma is now preparing for a United States investigational new drug submission by the end of 2026 and says a development partner is expected to support Phase 3 testing and lead commercialization.
The program could eventually address a commercially significant treatment market if the early tolerability profile is maintained and monthly dosing provides reliable therapeutic exposure. Mapi Pharma said oral cariprazine generated approximately $3.6 billion in worldwide revenue during 2025, illustrating the scale of the existing franchise that a long-acting injectable formulation could potentially extend. The company currently targets a New Drug Application submission in 2029 if Phase 3 development succeeds, although that timeline depends on regulatory agreement, completion of later clinical trials and the planned partnership.
Initial Cariprazine Depot data support continued testing but remain primarily a safety result
The ongoing study is a prospective, dose-escalating, open-label and multicenter Phase I/IIa trial evaluating pharmacokinetics, safety and tolerability of once-monthly subcutaneous Cariprazine Depot in participants considered eligible for oral cariprazine treatment. Following a washout period, participants in the first cohort received a single 22 mg subcutaneous injection. The broader study is designed to assess how the depot formulation releases cariprazine over time and whether monthly administration can maintain suitable exposure without introducing unacceptable tolerability problems.
The first cohort produced a favorable initial safety profile. No serious adverse events were reported, and all treatment-related adverse events associated with Cariprazine Depot were characterized as mild. Injection-site reactions were also mild, with injection-site pain resolving in less than one day on average. Mapi Pharma additionally reported that treatment-related adverse events unrelated to the injection site occurred in fewer participants and less frequently with Cariprazine Depot than during oral cariprazine exposure in the same patients.
These observations provide reassurance that the depot formulation did not produce an obvious new short-term safety problem in the initial cohort, but the dataset remains too early to define the product’s complete tolerability profile. The company has not disclosed enough patient-level information in the initial announcement to establish the frequency of individual adverse events, variability in drug exposure or how tolerability changes at higher doses. Later cohorts and repeated dosing will be more informative because a monthly depot product must maintain therapeutic exposure for weeks after each injection, leaving less flexibility to rapidly stop exposure if adverse effects emerge.
Pharmacokinetic results will therefore be just as important as the initial safety observations. A successful long-acting injectable needs to release sufficient cariprazine to maintain efficacy throughout the dosing interval while avoiding excessive early concentrations or accumulation after repeated injections. The current release did not provide detailed concentration curves, meaning the fundamental question of whether a single injection can reproduce appropriate cariprazine exposure for an entire month remains under evaluation.
Monthly administration could address adherence problems that complicate chronic psychiatric treatment
The rationale for a Cariprazine Depot formulation extends beyond convenience. Schizophrenia and bipolar disorder frequently require long-term treatment, and missed doses or medication discontinuation can contribute to symptom recurrence and hospitalization. Long-acting injectable antipsychotics are designed to reduce the need for daily medication-taking and provide clinicians with greater certainty that treatment has been administered.
Mapi Pharma is attempting to combine that long-acting treatment model with cariprazine, which is already established as an oral atypical antipsychotic. The medicine is approved for schizophrenia, manic or mixed episodes associated with bipolar I disorder, bipolar depression and adjunctive treatment of major depressive disorder. Mapi Pharma said Cariprazine Depot is being designed to provide sustained drug release for approximately one month following a subcutaneous injection.
The commercial opportunity could be meaningful because cariprazine already has broad physician familiarity and substantial existing sales. Mapi Pharma cited approximately $3.6 billion in global 2025 revenue for oral cariprazine, which is marketed in the United States by AbbVie under the Vraylar brand. The company also noted that the existing United States cariprazine capsule patent is expected to expire in 2029, the same year Mapi Pharma currently hopes to submit an NDA for its long-acting formulation.
That timing creates an interesting lifecycle-management opportunity. A successful monthly depot could provide a differentiated formulation as the original oral franchise approaches a period of greater generic competition. It would not automatically replace tablets, since many patients prefer oral treatment and long-acting injections introduce administration and injection-site considerations, but it could provide another option for patients and physicians concerned about adherence or frequent medication management.
A subcutaneous formulation could also differentiate Cariprazine Depot from some established intramuscular long-acting antipsychotics. Whether that translates into a meaningful practical advantage will depend on injection volume, administration requirements, tolerability and whether the product can eventually be given efficiently in outpatient psychiatric settings.
Mapi plans an FDA filing and Phase 3 partnership as development risk shifts toward exposure and efficacy
Mapi Pharma said it plans to submit an investigational new drug application to the United States Food and Drug Administration by the end of 2026. The company expects to work with a partner that would support the Phase 3 program and lead marketing, while Mapi Pharma would retain responsibility for manufacturing clinical and commercial supplies through its approved production facilities. If development succeeds, management currently anticipates a potential NDA submission in 2029.
The partnership component may become increasingly important as the program moves toward larger trials. Late-stage psychiatric studies can require hundreds of patients, multiple clinical sites and substantial investment, while commercializing a new antipsychotic formulation requires established relationships with psychiatrists, health systems and payers. Mapi Pharma did not identify the intended partner in its August 12 announcement, leaving the structure and economics of any future agreement unclear.
The planned development path must also establish whether a depot formulation can reliably reproduce the therapeutic effects already associated with oral cariprazine. Because the active medicine itself is established, much of the development risk centers on pharmacokinetics, dosing consistency, injection tolerability and demonstrating that the long-acting formulation maintains symptom control over the intended monthly interval.
Regulators will also need evidence supporting transitions between oral and depot treatment. Questions could include whether oral supplementation is needed when therapy begins, how quickly therapeutic concentrations are reached, what happens after missed injections and how clinicians should manage adverse events when active drug continues to be released from the depot.
These issues are particularly relevant for cariprazine because both the parent compound and its active metabolites already have prolonged pharmacokinetic characteristics after oral administration. A successful depot must demonstrate that extending exposure further produces predictable rather than excessively persistent drug levels.
The established cariprazine market raises the commercial ceiling while setting a high development bar
Mapi Pharma’s initial data are important because they show that its formulation has crossed the first human safety hurdle without an obvious tolerability signal that would prevent continued development. The result should not yet be interpreted as evidence that a monthly cariprazine injection will control schizophrenia, bipolar disorder or depression as effectively as daily oral therapy. The current study is primarily establishing whether the formulation behaves safely and predictably enough to justify that later test.
Commercially, the program benefits from targeting a molecule whose therapeutic relevance has already been established. Developers of entirely new antipsychotics must prove both that the pharmacology works and that clinicians will accept a new mechanism. Cariprazine Depot starts with a drug that has already generated billions of dollars in annual sales, which could reduce some market-education risk if the injectable ultimately receives approval.
The opposite side of that advantage is a demanding benchmark. A long-acting formulation must provide enough improvement in adherence, convenience or disease management to justify switching patients who are already stable on tablets. Safety and pharmacokinetic predictability will become especially important because the effects of a depot injection cannot be reversed as quickly as discontinuing an oral tablet.
The initial 22 mg cohort therefore represents only the beginning of the evidence needed to support Mapi Pharma’s commercial thesis. The more important milestones will be dose-escalation pharmacokinetics, repeated-dose tolerability, regulatory feedback on the United States development program and identification of the partner expected to finance Phase 3 and lead commercialization.
If those steps progress as planned, Cariprazine Depot could emerge as a significant lifecycle extension for one of the larger modern antipsychotic franchises. For now, the Phase I/IIa result establishes something more limited but necessary: Mapi Pharma has shown that its once-monthly formulation can enter humans without an immediate safety obstacle, giving the company a credible reason to proceed toward the much more demanding clinical and regulatory tests ahead.
